Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

Lantern Pharma, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced the addition of two senior industry executives to support the Company’s clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manager, where she will be responsible for oversight of the planned clinical trials, including the planned Phase 2 clinical trial of LP-300 as a combination therapy in never-smokers with Non-Small Cell Lung Cancer (NSCLC).

Recommended AI News: UnDigital Turns e-Commerce Packages Into Targeted, Measurable Marketing Channel

Dr. Kochat brings 30 years of experience with multiple successful drug candidates and management of teams of all phases and sizes in CMC, GxP and GLP, as well as quality regulatory affairs. He has years of hands-on experience authoring, reviewing and approving GMP quality documents, including 3 oncology NDAs, 4 ANDAs, and 13 preclinical programs, as well as oversight of CMOs and CROs. Most recently, Dr. Kochat has served as Director, Pharmaceutical Operations & Business Development at the Plough Center for Sterile Drug Delivery Solutions (UTHSC), Memphis, where his responsibilities have included leading all end-to-end operations related to cGMP manufacturing and quality affairs, including development, site registration and launch of a sterile, cGMP fill-finish facility. Dr. Kochat received a Ph.D. degree in Organic Chemistry from Purdue University, followed by NIH fellowships at Purdue University and Rice University, as well as M.Sc. and B.Sc. degrees in Chemistry from the University of Kerala, India. Dr. Kochat has co-invented more than 225 issued domestic and international patents and co-authored over 65 peer journal scientific publications.

Related Posts
1 of 20,650

Recommended AI News: Simone Biles Partners with Autograph

Ms. Bunpian is a seasoned and certified research professional with 15+ years of experience, including clinical research, project management, study start up, regulatory submissions, and budgeting.  Most recently, she served as Research Project Manager and Clinical Research Coordinator with Baylor Scott & White Heath, where she oversaw clinical trials in various therapeutic areas, including GI cancer, neurology, rheumatology, and abdominal transplant research. She has years of hands-on experience in running industry-sponsored and investigator-initiated clinical trials according to ICH Good Clinical Practices, as well as federal laws and regulations. Before transitioning to clinical research, Ms. Bunpian worked for several years as a Research Associate in gene expression and DNA sequencing at the University of Texas Southwestern Medical Center and Lexicon Pharmaceuticals. Ms. Bunpian received a BS degree in cell and molecular biology from Tulane University and an MPH degree from the University of Texas School of Public Health.  Ms. Bunpian also holds the ACRP-CP certification through the Association of Clinical Research Professionals.

Panna Sharma, President & CEO of Lantern Pharma, stated, “Our entire team welcomes these two accomplished and experienced industry executives to our leadership team. Each of them brings a strong track record overseeing and delivering large drug development initiatives, ensuring they are completed on time, within budget and to the highest quality standards that can lead to positive patient impact. We are building a world-class team to support our anticipated growth, as we execute on our mission of transforming the cost, risk and timeline of drug development by leveraging our proprietary RADR A.I. platform.”

Recommended AI News: Rigel Protocol Is Bringing DeFi to Everyone With The Gifting DApp

Comments are closed.